PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

MHRA approves Seagen’s Tukysa for HER2-positive breast cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Seagen’s Tukysa in combination with trastuzumab and capecitabine for the treatment of advanced HER2-positive breast cancer.

Specifically, the MHRA has authorised the Tukysa combination for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have previously been treated with at least two prior anti-HER2 treatment regimens.

The authorisation is based on results from Seagen’s HER2CLIMB trial, that enrolled 612 patients with HER2-positive unresectable locally advanced or metastatic breast cancer who had previously received – separately or in combination –  trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1).

Results from this trial showed patients who were treated with Tukysa in combination with trastuzumab and capecitabine had a 46% reduction in the risk of cancer progression or death – progression free survival (PFS).

The addition of Tukysa also reduced the risk of death by 34%, with a median overall survival (OS) of 21.9 months for the Tukysa group compared to 17.4 months for placebo.

“The Tukysa combination is a landmark therapy for patients with HER2-positive metastatic breast cancer with or without brain metastases, extending overall survival in these patients after two prior anti-HER2-treatment regimens,” said Clay Siegall, chief executive officer at Seagen.

“We are pleased Tukysa is now authorised in the UK, and we look forward to further collaborating with the national reimbursement bodies to ensure it is available to adult patients,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026